Dive in
We have our own point of view on the people, technologies, and conversations that will shape the future.
The single greatest health concern facing American kids and teens today is a crisis in mental health.
Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.
Riva Health founders Tuhin Sinha and Dag Kittlaus discuss their critical mission to revolutionize cardiovascular healthcare; their long histories with Menlo partners Greg Yap and Shawn Carolan; how they were introduced to each other; and the whirlwind journey to FDA approval.
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.
Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.
Ophelia is reinventing addiction treatment and dramatically improving access to best-in-class care with telemedicine.
In the face of a national emergency in child and adolescent mental health, urgent measures are needed to help those in need.
Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship
Riva’s mission is to improve cardiovascular disease worldwide using just the smartphones that people already have in their pockets, replacing 130-year-old blood pressure cuff technology.
Opioid use disorder (OUD) is an epidemic that will define our generation. Roughly 90 million Americans use opioids and over 10 million misuse them.
We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.
At Menlo, we believe the pace of innovation in new medicines will continue to accelerate, powered by the combination of advances in biology, advances in information technology, and even the lasting implications of the global pandemic.
Here at Menlo, we are building an investing practice focused on three of the most exciting areas of healthcare: therapeutic platforms, digital health, and transformative technologies.
Nearly half of U.S. adults—108 million people—have high blood pressure, which is the #1 controllable risk for both heart disease and stroke, the two leading worldwide causes of death.
H1 is a unique healthcare data SaaS company with proprietary data, compelling initial applications, and potential to expand.
